top of page

Morphocell Technologies appoints Didier Leconte as an independent member of its Board of Directors

DidierLeconteHR Vertical_edited.jpg

Montreal, QC, May 2, 2024  – Morphocell Technologies, a leader in the field of cell therapy, is thrilled to announce the appointment of Didier Leconte as an independent member of its Board of Directors, effective immediately.


Mr. Leconte brings a wealth of experience and a proven track record of success in the life sciences and biotechnology sectors. Over the years, he has been instrumental in shaping Quebec’s aggressive strategy in support of Life Sciences. He previously held significant roles such as Vice-President of Investments in Life Sciences at the Fonds de solidarité FTQ and Vice-President of Investments in Life Sciences and Technology at Investissement Québec, where he played a crucial role in fostering innovation and investment in healthcare technologies​​. His leadership in various board positions for many successful companies at different stages of development, including his presidency at adMare BioInnovations, underscores his deep commitment to advancing life sciences across Canada​​.

Massimiliano Paganelli, CEO of Morphocell Technologies, expressed his enthusiasm about Mr. Leconte’s appointment, stating, “Didier’s exceptional background in life sciences investment and his vision for innovation and growth perfectly align with our goals at Morphocell. His expertise will be invaluable as we continue to develop groundbreaking treatments for patients and strengthen Quebec’s position as a biotechnology hub.”

Mr. Leconte shared his excitement about joining the Morphocell board, remarking, “I am honored to be part of a pioneering company like Morphocell Technologies. This opportunity aligns with my commitment to supporting high-potential biotech firms and advancing transformative healthcare solutions. I look forward to contributing to Morphocell’s mission of innovation and its impact on the global stage.”

This strategic appointment highlights Morphocell Technologies' commitment to enhancing its governance and strategic direction. Mr. Leconte’s experience is set to play a pivotal role in Morphocell’s growth and its contribution to Quebec’s and Canada’s biotechnology ecosystem, driving value creation for the company and its stakeholders.


About Morphocell Technologies:

Morphocell Technologies Inc. is a Laval (QC)-based regenerative medicine company focused on the development and commercialization of stem cell-derived tissue and organ replacement therapies. Its iPSC-derived platform technology has a large pipeline potential touching different organ deficiencies, with severe liver disease being the initial focus. Morphocell prides itself on its culture of innovation, technical excellence, and commitment to improving patients' lives. 


Media Contact:

Zaynah Ibrahim

+ 1 (514) 373-6444 ext. 106

bottom of page